Stockreport

Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript [Seeking Alpha]

OREXO AB SP/ADR  (ORXOY) 
NASDAQ:AMEX Investor Relations: orexo.com/en/investors
PDF Company Participants Nikolaj Sørensen - President & CEO Frederik Jarrsten - Executive VP & CFO Conference Call Participants Klas Palin - DNB Carnegie Commission [Read more]